Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
  • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
  • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
  • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2121/00—Preparations for use in therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2123/00—Preparations for testing in vivo

Definitions

• the present invention relates to macroaggregates of copper-64 and gelatin as well as to a method of preparation of macroaggregates of thin type and to their uses in human medicine, one application for which these macroaggregates are of particular interest being in the field of pulmonary scintiscanning by intravenous injection.
• a radioactive preparation which is intended to be employed in pulmonary scintiscanning must exhibit properties which permit retention of said preparation at the level of the pulmonary alveoli without causing any permanent obstruction of the capillary system. This entails the need to ensure that the particles of a preparation of this type must be of sufficiently large size in order to be efiFective while remaining sufficiently small and friable to ensure that the aggregate which is formed by said particles can readily be broken down by the blood stream.
• a particle diameter of the order of 50 microns makes it possible to satisfy these two conditions.
• this invention relates to the novel industrial product which is constituted by the macroaggregates of copper-64 and gelatin.
• the invention is also concerned with a method of preparation of macroaggregates of copper-64 and gelatin which essentially consists in forming a copper-gelatin compleX by addition in the cold state of an alkaline solution of copper-64 to a solution of gelatin, in precipitating said complex in the hot state with a solution of tannin 'ice and in completing the suspension obtained by addition of distilled water, the proportions being calculated so as to maintain a pH in the vicinity of 7 or in other words a neutral value and in such a manner as to ensure that said suspension does not contain any copper in the ionic form or any gelatin which has remained in solution.
• the present invention is further concerned with the applications of the macroaggregates of copper-64 and gelatin in the field of human medicine.
• the copper chloride obtained is washed a number of times, then crystallized and retreated with a small quantity of water. There are then added 3.8 cm. of an 8% solution of double tartrate of sodium and potassium, then 1 cm. of a 2 N sodium hydroxide solution and finally the quantity of distilled water which is necessary to produce a volume of 7.8 cm, which corresponds to a concentration of 6.4 mg. of copper-64 per liter.
• stage (d) Formation of the macroaggregates
• the complex obtained in stage (c) is precipitated and heated to a temperature of 50 C. by addition of 0.25 cm. of a 12% solution of tannin and the suspension is completed to 10 cm. by addition of distilled water.
• the proportions given above satisfy these ditferent conditions and result in the production of macroaggregates which are suitable for use in pulmonary scintiscanning.
• the diameter of the particles thus obtained is suitably of the order of 50 microns and must in any case always be greater than 30 microns; this diameter varies slightly as a function of the proportion of gelatin and of tannin.
• the macroaggregates in accordance with the present invention can find applications other than pulmonary scintiscanning (e.g. scintiscanning of the liver) and that a given particle diameter corresponds to each particular application.
• pulmonary scintiscanning e.g. scintiscanning of the liver
• each particle having a diameter greater than 30 microns and on the order of 50 microns.
• a method of pulmonary scintiscanning in humans consisting of the step of injecting intravenously the complex of claim 1 into the patient. 7
• a method of preparing a copper-64/gelatin complex, each particle having a diameter greater than 30 microns and on the order of 50 microns consisting of the steps of mixing an alkaline solution of a copper-64 salt and a solution of gelatin in the cold state, heating the mixture, precipitating a copper-64/gelatin complex by the addition of a solution of tannin, and completing the precipitation by the addition of distilled water, the proportions of the ingredients used leaving substantially no copper-64 or gelatin in solution in uncomplexed form.
• the alkaline solu- 7 tion of the copper-64 salt being prepared by treating copper-64 chloride with aqueous sodium hydroxide in the presence of sodium potassium tartrate.
• gelatin solution being prepared by a dispersing gelatin in hot distilled water and sterilizing the resulting solution in an autoclave.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Optics & Photonics (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Dispersion Chemistry (AREA)
• Physics & Mathematics (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Nanotechnology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=9034721

Family Applications (1)

Country Status (5)

Cited By (3)

• 1969
  • 1969-05-28 FR FR6917455A patent/FR2043487A1/fr active Pending
• 1970
  • 1970-05-18 US US00038489A patent/US3743712A/en not_active Expired - Lifetime
  • 1970-05-21 GB GB24624/70A patent/GB1276205A/en not_active Expired
  • 1970-05-22 BE BE750785D patent/BE750785A/xx unknown
  • 1970-05-22 DE DE19702025095 patent/DE2025095A1/de active Pending

Also Published As

Similar Documents